MCCLUNG BARBARA G 4

4 · Caribou Biosciences, Inc. · Filed Oct 21, 2021

Form 4

Period: 2021-10-20

Chief Legal Officer

Transactions

Purchase
Common Stock
2021-10-20$2.69/sh+9,176$24,683→ 342,801 total
Purchase
Common Stock
2021-10-20$2.69/sh+43$116→ 342,844 total
Exercise of In-Money
Option to purchase Common Stock
2021-10-20−9,176→ 80,951 total
Exercise: $2.69Exp: 2029-09-30→ Common Stock (9,176 underlying)
Exercise of In-Money
Option to purchase Common Stock
2021-10-20−43→ 89 total
Exercise: $2.69Exp: 2028-06-11→ Common Stock (43 underlying)

Footnotes (5)

[F1]These shares were acquired pursuant to the exercise of a stock option, as reported in Table II below.
[F2]The exercise price for this stock option was incorrectly reported as $2.68 per share on the reporting person's Form 3 filed on July 22, 2021.
[F3]The amount of securities beneficially owned was incorrectly reported as 333,626 shares on the reporting person's Form 3 filed on July 22, 2021. The correct number is 333,625.
[F4]The shares subject to this option have vested or will vest in equal monthly installments until the option is fully vested on October 1, 2023, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.
[F5]The shares subject to this option have vested or will vest in equal monthly installments until the option is fully vested on June 12, 2022, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.

Documents

1 file